Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRESBIEN triplet therapy study in early-relapse BRAF V600E-mutated colorectal cancer
jRCTs051210152Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started Jan 2022; status: active, not recruiting.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051210152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210152.